pimobendan has been researched along with Ventricular Dysfunction, Left in 3 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To assess the effects of phosphodiesterase type 3 and phosphodiesterase type 5 inhibitors on cardiac function and left ventricular myocardial fibrosis in catecholamine-induced myocardial injury, sildenafil and pimobendan were administered to male Wistar rats 24 hours after isoproterenol injection." | 7.91 | Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. ( Nakata, TM; Shimada, K; Suzuki, K; Tanaka, R; Uemura, A, 2019) |
| " To assess the effects of phosphodiesterase type 3 and phosphodiesterase type 5 inhibitors on cardiac function and left ventricular myocardial fibrosis in catecholamine-induced myocardial injury, sildenafil and pimobendan were administered to male Wistar rats 24 hours after isoproterenol injection." | 3.91 | Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. ( Nakata, TM; Shimada, K; Suzuki, K; Tanaka, R; Uemura, A, 2019) |
| "Pimobendane was given to Case 2." | 1.33 | [Subarachnoid hemorrhage complicated with different manifestations of transient abnormal left ventricular wall motion: two case reports]. ( Hoshida, T; Inoue, F; Saito, Y; Shiono, S; Tabuse, H; Thoma, Y; Tsuzuki, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakata, TM | 1 |
| Suzuki, K | 1 |
| Uemura, A | 1 |
| Shimada, K | 1 |
| Tanaka, R | 1 |
| Inoue, F | 1 |
| Tsuzuki, T | 1 |
| Thoma, Y | 1 |
| Shiono, S | 1 |
| Tabuse, H | 1 |
| Hoshida, T | 1 |
| Saito, Y | 1 |
| Duncker, DJ | 1 |
| Haitsma, DB | 1 |
| Liem, DA | 1 |
| Heins, N | 1 |
| Stubenitsky, R | 1 |
| Verdouw, PD | 1 |
3 other studies available for pimobendan and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Collagen Type I; Collagen Type III; Disease Models, Animal; Fibrosis; | 2019 |
[Subarachnoid hemorrhage complicated with different manifestations of transient abnormal left ventricular wall motion: two case reports].
Topics: Cardiotonic Agents; Catecholamines; Echocardiography; Electrocardiography; Female; Humans; Male; Mid | 2006 |
Beneficial effects of the Ca2+ sensitizer EMD 57033 in exercising pigs with infarction-induced chronic left ventricular dysfunction.
Topics: Animals; Calcium; Cardiotonic Agents; Chronic Disease; Exercise Test; Female; Hemodynamics; Male; My | 2001 |